Zurn Elkay (ZWS) Q3 2026 Earnings Call Transcript

Zurn Elkay reported third-quarter net sales of $495.1 million, up 9% reported and 7% on a core basis, while adjusted EBITDA rose 15% to $140.1 million and margin expanded 150 bps to 28.3%. The company raised full-year 2026 adjusted EBITDA guidance to $512 million–$515 million, targeting more than $350 million in free cash flow; it also announced an 18% increase in its annual dividend and repurchased $35 million of shares. Management cited economic and end-market uncertainty heading into 2027, but expects incremental margins of at least 40% and sees growth opportunities from the Intellihot acquisition and Runpoint product launch.

Analysis

The key underwriting tension is that earnings power is becoming less dependent on market growth—but the 2027 margin algorithm is now carrying more of the investment case. A softer construction backdrop can be partly cushioned by MRO, institutional demand and share gains; however, 40%+ incremental margins and the SKU-simplification benefit need to convert into reported results, not just offset weaker volumes. Price comparisons also become less supportive after the tariff-related price carryover rolls off, so track unit volume and core growth separately from acquisition contribution.

Near term, Q4 seasonality and the guided sales step-down may dominate the tape; do not extrapolate Q3 margins mechanically. Over 1–3 months, February’s 2027 guidance is the catalyst: the decisive evidence will be whether management can sustain core growth and margins despite its own expectation of a softer market. Over 6–18 months, Intellihot plus Runpoint could create channel leverage and expand the addressable hot-water offering, but the stated opportunity is not yet proof of adoption, attach rates or attractive returns on the acquisition cost. Data-center demand is a useful pocket, not a reliable proxy for broad commercial construction.

Contrarian angle: the market may focus on the down-market setup and underweight the resilience of retrofit and institutional work; the opposite risk is treating a strong operating model as evidence that growth is immune to a weakening market. The thesis weakens if core growth turns negative, incremental margins fall materially short of 40%, or Runpoint/Intellihot fail to gain customer traction. Verify organic volume, SKU savings realization, and acquisition returns before underwriting durable multiple expansion.

Key Decisions for Investors

• Prefer a staged long ZWS on post-earnings or Q4-seasonality weakness rather than chasing results. Add only if core growth remains positive and margins track toward management’s 2027 framework; reduce if volume-led core growth deteriorates or incremental margins miss materially.
• For a relative-value expression, consider long ZWS versus short XHB: the intended exposure is ZWS’s institutional/MRO mix against a more housing-sensitive basket, not a claim that ZWS is insulated from construction weakness. Reassess if residential weakness spreads into ZWS’s retrofit or institutional demand.
• Treat Runpoint and Intellihot as watch items, not yet standalone growth underwriting. Seek evidence in 2027 disclosures on adoption, recurring service revenue, channel conversion and returns on invested capital before crediting meaningful valuation upside.
• Monitor February guidance and quarterly cash conversion. Falsifiers include negative core growth, failure to realize the cited SKU-related EBITDA benefit, or free cash flow weakening after excluding tariff-related effects.